A61P 11 - Drugs for disorders of the respiratory system

Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
12/2004
12/07/2004	US6828440 Analgesics; side effect reduction
12/07/2004	US6828418 Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
12/07/2004	US6828348 L-ascorbic acid-2-o-maleic acid-a-tocopherol diester 1-propanol adduct and process for producing the same
12/07/2004	US6828342 Nitrate salts of Salbutamol, Cetirizine, Loratadine, Terfenadine, Emedastine, Ketotifen, Nedocromil, Ambroxol, Dextromethorphan, Dextorphan, Isoniazide, Erythromycin, and Pyrazinamide; respiratory system pathology treatment
12/07/2004	US6828338 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
12/07/2004	US6828337 Bicyclic retinods containing ester or acid group; useful for treating emphysema
12/07/2004	US6828333 Ether derivatives useful as inhibitors of PDE4 isozymes
12/07/2004	US6828327 Macroheterocylic compounds useful as kinase inhibitors
12/07/2004	US6828319 Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof
12/07/2004	US6828315 1-Amino triazoloc4,3-a! quinazoline-5-ones and/or -5-thiones inhibiting phosphodiesterase IV
12/07/2004	US6827946 Compositions containing both sedative and non-sedative antihistamines
12/07/2004	US6827935 Method of and compositions for immunization with the pseudomonas V antigen
12/02/2004	WO2004103998A1 Quinoline derivatives as phosphodiesterase inhibitors
12/02/2004	WO2004103992A1 2-aminoquinoline derivative
12/02/2004	WO2004103970A1 Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists
12/02/2004	WO2004103954A1 Amide derivative
12/02/2004	WO2004103407A2 Composition comprising a pde4 inhibitor and a pde5 inhibitor
12/02/2004	WO2004103403A1 Immunocompetent cell activation inhibitor and use thereof
12/02/2004	WO2004103399A1 Use of ulinastatin for treating severe acute respiratory syndrome and pharmaceutical composition of ulinastatin
12/02/2004	WO2004103379A1 Salmeterol and ciclesonide combination
12/02/2004	WO2004103364A2 Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors
12/02/2004	WO2004026815A3 Phenol derivatives and their use as rotamase inhibitors
12/02/2004	WO2004020584A3 Antagonists of chemokine receptors
12/02/2004	WO2003095667A3 Autoimmune conditions and nadph oxidase defects
12/02/2004	WO2003064387A3 Substituted indoles as alpha-1 agonists
12/02/2004	US20040242928 Reverse hydroxamic acid derivatives
12/02/2004	US20040242890 Agonists of beta-adrenoceptors
12/02/2004	US20040242871 Nitric oxide synthease inhibitors; antiinflamamtory agents; analgesics; inflamamtory bowel disorders; antiarthritic agents;
12/02/2004	US20040242868 Controlling cytokines; antiinflammatory agents; rheumatic disoreders; skin disorders; respiratory system disorders; Alzheimer's disease; Parkinson's disease; Huntington"s disease ; amyotrophic lateral sclerosis
12/02/2004	US20040242859 Moraxella (branhamella) catarrhalis polypeptides and corresponding dna fragments
12/02/2004	US20040242842 Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use
12/02/2004	US20040242672 Pyrrolidine derivatives
12/02/2004	US20040242656 N-heterocyclicamide compounds; useful in the treatment of cardiovascular disorders, in particular, as an anticoagulant
12/02/2004	US20040242654 Diaryl ether derivative, addition salt thereof, and immunosuppressant
12/02/2004	US20040242651 to gastrointestal systems, kidneys
12/02/2004	US20040242643 phosphodiesterase 4 inhibitors in immunocompetent cells, such as macrophages and lymphocytes; side effect reduction; N-(3,5-dichloro-1-oxopyridin-4-yl)-[7-hydroxy-1-(3- or 2-nitrobenzyl)-indol-3-yl]glyoxylamide
12/02/2004	US20040242638 Treatment of rhinitis with steroids as antiallergens
12/02/2004	US20040242629 Quinuclidine carbamate derivatives and their use as M3 antagonists
12/02/2004	US20040242627 2-Iminoimidazole derivatives (1)
12/02/2004	US20040242595 Pyrimidine derivatives
12/02/2004	US20040242577 N-methyl 2-morpholine-4-carbonyl or sulfonyl substituted; for example: 2-{[4-(3,4-dichlorophenoxy)piperidin-1-yl]methyl}morpholine; useful for treating asthma and/or rhinitis
12/02/2004	US20040242575 for use with various disorders including sleep disorders; depression; cardiovascular disorders; pain; neurodegenerative disorders; psychiatric disorders etc.
12/02/2004	US20040242573 Novel compounds
12/02/2004	US20040242569 Quatemary ammonium compounds
12/02/2004	US20040242567 alone or in combination with a diuretic agent; diabetic nephropathy
12/02/2004	US20040242564 1,2,3,4-tetrahydroisoquinolines derivatives
12/02/2004	US20040242507 Topical formulations of a lipophilic anthracycline with a second active ingredient and carrier; antiproliferative agents for skin and mucus membrane disorders; side effect reduction in psoriasis treatment with valrubicin
12/02/2004	US20040242455 which exerts potent and selective activated blood coagulation factor X inhibitory activity and is useful for prevention or treatment of disease associated therewith
12/02/2004	US20040241803 25 human secreted proteins
12/02/2004	US20040241705 Method of determining a chemotherapeutic regimen based on glutathione-s-transferase pi
12/02/2004	US20040241255 Pharmaceutical composition containing valerina officinalis extract
12/02/2004	US20040241236 shell provides a delay of greater than one hour for the onset of dissolution of the active ingredient upon contacting of the dosage form with a liquid medium such as water or gastrointestinal fluids, and the delay is independent of the pH
12/02/2004	US20040241232 Comprising inhalable medicament particles having a mass median aerodynamic diameter no greater than 10 mu m and 50% of a non-respirable excipient fraction comprising low density excipient particles having an aerodynamic diameter greater than 10 mu m and a geometric diameter greater than 30 mu m
12/02/2004	US20040241226 Administering a tyrosine kinase inhibitor, more particularly a non toxic, potent and selective c-kit inhibitor, wherein said inhibitor is unable to promote death of IL-3 dependent cells cultured to presence of IL-3
12/02/2004	US20040241208 Comprising an active ingredient and a carbohydrate, at least a portion of which carbohydrate is crystallized and has an average particle size of 2 to 35 microns, composition having a moisture content of 10 to 13 percent; soft tablet
12/02/2004	US20040241184 Fermentation product of cyptoporous volvatus and its preparation method and use
12/02/2004	US20040241176 Method of producing membrane vesicles
12/02/2004	US20040241156 Gene expression inhibition; solid phase synthesis; drug screening; for treating cancer, central nervous system disorders, and chronic obstructive pulmonary disorder
12/02/2004	US20040241154 Secretin for the treatment of asthma
12/02/2004	DE202004013365U1 Nasal spray for treatment of acute and/or chronic nose cavity inflammation contains vitamin C dissolved in a carrier substance
12/02/2004	CA2526374A1 2-aminoquinoline derivatives
12/02/2004	CA2526222A1 Treatment of respiratory disease associated with matrix metalloprotease inhibitors
12/02/2004	CA2526013A1 Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists
12/02/2004	CA2525946A1 Composition comprising a pde4 inhibitor and a pde5 inhibitor
12/02/2004	CA2525943A1 Salmeterol and ciclesonide combination
12/02/2004	CA2489124A1 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
12/01/2004	EP1481989A1 A-33 related antigens and their pharmacological uses
12/01/2004	EP1481976A1 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
12/01/2004	EP1481969A1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient
12/01/2004	EP1481665A1 Novel lipid mixtures for synthetic surfactants
12/01/2004	EP1480996A1 Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form
12/01/2004	EP1480993A2 Desaturase genes, enzymes encoded thereby, and uses thereof
12/01/2004	EP1480973A1 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
12/01/2004	EP1480972A2 Compounds possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders
12/01/2004	EP1480962A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
12/01/2004	EP1480959A1 Piperazine derivatives as anti-inflammatory agents
12/01/2004	EP1480954A1 Vanilloid receptor modulators
12/01/2004	EP1480671A2 Recombinant rsv virus expression systems and vaccines
12/01/2004	EP1480667A1 Compositions comprising pulmonary surfactants and a polymyxin having improved surface properties
12/01/2004	EP1480626A1 Ambroxol for treating painful conditions in the mouth and pharyngeal cavity
12/01/2004	EP1480615A1 Formoterol superfine formulation
12/01/2004	EP1480598A2 Manipulation of cytokine levels using cd83 gene products
12/01/2004	EP1358180B1 Naphthostyril derivatives and their use as inhibitors of cyclin-dependent kinases
12/01/2004	EP1318996B1 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
12/01/2004	EP1183040B1 Therapeutic use of an inhibitor of a hedgehog signalling pathway
12/01/2004	EP1117388A4 Antioxidant gel for gingival conditions
12/01/2004	CN1551914A FAD4, FAD5, FAD5-2 and FAD6, novel fatty acid desaturase family members and uses thereof
12/01/2004	CN1551877A Piperidine derivatives useful as CCR5 antagonists
12/01/2004	CN1551769A Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
12/01/2004	CN1551763A Novel treatment method
12/01/2004	CN1551760A Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
12/01/2004	CN1550235A Use of heparin-binding antagonists in the inhibition of bradykinin release
12/01/2004	CN1177860C Cholenic acid amides and pharmaceutical compositions thereof
12/01/2004	CN1177844C Cyclopropanes as CGRP antagonists, medicaments contg. said compounds and method for production thereof
12/01/2004	CN1177831C New benzimidazolone-benzoxazolone-, or benzothiazoloe derivatives as ion channel modulating agents
12/01/2004	CN1177830C Benzoheterocycles and their use as MEK inhibitors
12/01/2004	CN1177828C Novel hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines
12/01/2004	CN1177825C Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use thereof as medicaments
12/01/2004	CN1177615C Arteriovenous and venous graft treatment methods and compsns.
12/01/2004	CN1177597C Nose drops for rhinitis

1 ... 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 ... 878